|
Chronic Lymphocytic Leukemia
|
0.440 |
Biomarker
|
disease |
BEFREE |
The survival of chronic lymphocytic leukaemia (CLL) cells, among other cancer cells, is assisted by the deregulation of nuclear to cytoplasmic shuttling, at least in part through deregulation of the transport receptor XPO1 and the constitutive activation of PI3K-mediated signaling pathways.
|
31710039 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
Excepting NOTCH1, TP53 and XPO1, which showed a lower incidence in MBL, genes were mutated with a similar prevalence to CLL, indicating the early origin of most driver mutations in the MBL/CLL continuum.
|
27469216 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
Biomarker
|
disease |
BEFREE |
Together, these findings demonstrate that XPO1 is a valid target in CLL with minimal effects on normal cells and provide a basis for the development of SINEs in CLL and related hematologic malignancies.
|
23034282 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
Two recent studies reported whole-genome sequencing of chronic lymphocytic leukemia (CLL) samples and found repeated mutations in the XPO1 and NOTCH1 genes.
|
22086416 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.440 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
XPO1 was higher expressed in PCa compared to NAP in the MS data analysis (P > 0.0001).
|
31018022 |
2019 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Therefore, XPO1 inhibition could be a novel promising agent used in combination with conventional chemotherapeutics and AR-targeted therapy for the better treatment of PCa, especially CRPC.
|
30450161 |
2018 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
This was clinically tested in prostate cancer tissue and shown that cytoplasmic PML and CRM1 co-expression correlates with reduced disease-specific survival.
|
26549027 |
2016 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
|
23507703 |
2013 |
|
Mediastinal (Thymic) Large B-Cell Lymphoma
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Although the immunophenotype and XPO1 mutation are characteristic of PMBL, EBV expression is uncommon.
|
31789821 |
2019 |
|
Mediastinal (Thymic) Large B-Cell Lymphoma
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Targeted next-generation sequencing analysis showed SOCS1 mutations in the 3 cases, and TNFAIP3 and XPO1 mutations in one, further supporting the diagnosis of PMBL.
|
30211726 |
2019 |
|
Mediastinal (Thymic) Large B-Cell Lymphoma
|
0.320 |
GeneticVariation
|
disease |
ORPHANET |
Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
|
27312795 |
2016 |
|
Atrial Fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
The long tail of oncogenic drivers in prostate cancer.
|
29610475 |
2018 |
|
Paroxysmal atrial fibrillation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Persistent atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
familial atrial fibrillation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Mammary Neoplasms
|
0.120 |
Biomarker
|
group |
BEFREE |
Remodeling metabolic pathways to regenerate new vulnerabilities in endocrine resistant breast tumors is novel, and given the need for better strategies to improve therapy response in relapsed ERα (+) tumors, our findings show great promise for uncovering the role that ERα-XPO1 crosstalk plays in reducing cancer recurrences.
|
30987380 |
2019 |
|
Mammary Neoplasms
|
0.120 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Mammary Neoplasms
|
0.120 |
GeneticVariation
|
group |
BEFREE |
Using advanced statistical methods, we found that expression levels of several of nuclear transport genes including XPO1 were associated with poor survival and predicted recurrence of tamoxifen-treated breast tumors in human breast cancer gene expression data sets.
|
27533791 |
2016 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
|
31822399 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Over-expression of the protein transporter exportin-1 (XPO1) leads to mislocalization of tumor suppressor proteins (TSPs) and their inactivation.
|
31831564 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By inhibiting the primary export protein, XPO1, selinexor localizes and activates tumor suppressor proteins in the nucleus and inhibits DNA damage repair, rationalizing combination with DNA-damaging agents.
|
31636097 |
2020 |